North America Biosurgery Market Outlook, 2031

Market Drivers

• High and growing surgical volumes across all specialties: North America performs tens of millions of surgical procedures annually, with the United States alone accounting for approximately 40 million to 50 million major surgical procedures. The breadth and depth of surgical activity ensure that biosurgical products particularly hemostatic agents and sealants are utilized in virtually every operating room. The continued expansion of surgical capacity, driven by hospital modernization, ASC development, and workforce growth, further reinforces this demand driver. In Canada, healthcare expenditure and surgical volumes continue to rise, while Mexico's growing surgical procedure volume indicates a robust demand for surgical support products.
• Aging population and increasing prevalence of chronic diseases: The aging North American population represents the most significant long-term demand driver. As the cohort of people aged 65 and older continues to expand, the incidence of degenerative joint diseases, spinal disorders, cardiovascular conditions, and cancers requiring surgical intervention rises correspondingly. The increasing prevalence of chronic diseases, including cardiovascular disorders, cancer, and orthopedic conditions, is leading to more surgical interventions and driving demand for biosurgical products. In Canada, the aging population and increasing investments in surgical innovation are driving steady growth.
• Advanced healthcare infrastructure and technological innovation: North America benefits from a highly developed network of hospitals, specialized surgical centers, and ambulatory surgical centers, enabling broader access to biosurgical products and advanced surgical procedures. The region's well-established healthcare infrastructure provides the foundation for high surgical volumes and the broad utilization of biosurgical products. Continuous technological advancements in biosurgery products, including advanced hemostatic agents, synthetic sealants, and bioactive bone grafts, are expanding the addressable market and driving adoption across healthcare facilities.

Market Challenges

• Pricing pressure and cost-containment initiatives: Despite the market's size and sophistication, biosurgery manufacturers face persistent pricing pressure from hospital procurement organizations, group purchasing organizations (GPOs), and government payers. The high costs of advanced biosynthetic products pose challenges for widespread adoption, particularly in cost-sensitive healthcare settings. In the United States, CMS reimbursement policies play a decisive role in determining product adoption, while in Canada, centralized procurement through provincial health authorities exerts pricing pressure. In Mexico, public health system procurement and price sensitivity create distinct pricing dynamics.
• Regulatory complexity and compliance burdens: The regulatory landscape in North America presents challenges for biosurgery manufacturers. The U.S. Food and Drug Administration (FDA) regulates biosurgical products through the 510(k) premarket notification pathway, the Premarket Approval (PMA) pathway, and the De Novo classification process. In Canada, Health Canada's Medical Devices Directorate oversees product approval. In Mexico, COFEPRIS regulates medical devices under the Health General Law. Navigating these regulatory requirements increases time-to-market and compliance costs.
• Healthcare workforce constraints and infrastructure gaps: Despite significant healthcare investment, North America faces workforce challenges that could impact surgical capacity. Geographic disparities further limit adoption, particularly in rural and remote regions of Canada and underserved areas of Mexico. These workforce and infrastructure constraints may limit adoption of premium-priced advanced biologics in certain regions.

Market Trends

• Accelerating shift to ambulatory surgical centers and outpatient settings: The North America biosurgery market is undergoing a fundamental structural transformation as surgical care continues its long-term migration from inpatient hospitals to ambulatory surgical centers (ASCs) and outpatient settings. As of Q2 2025, there are 12,294 total ASCs operating nationwide in the United States, including 6,504 Medicare-certified facilities. For biosurgery manufacturers, this trend requires adaptation of product portfolios developing formulations and delivery systems optimized for the fast-paced, high-throughput ASC environment and adjustment of commercial strategies to target the growing ASC customer base.
• Growing adoption of minimally invasive and robotic-assisted surgery: North American healthcare systems are at the forefront of adopting minimally invasive and robotic-assisted surgical techniques. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand.
• Technological innovation in biomaterials and surgical delivery systems: Continuous innovation in biosurgery products is expanding the addressable market. Next-generation hemostatic agents with faster action times, synthetic sealants with enhanced wet-tissue adhesion, and bioactive bone grafts with regenerative capabilities are creating new clinical applications and premium-pricing opportunities. North America leads in the adoption of these advanced technologies, supported by well-established healthcare infrastructure and favorable reimbursement policies.